Paper Details

  1. Home
  2. Paper Details

Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.

Author: CaronJ, HandleyD A, NoonanM, RollinsT E, SniderM E, TinkelmanD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Levalbuterol, the single isomer version of albuterol, provides significant bronchodilatory activity and is well-tolerated. Lower doses of levalbuterol may be associated with fewer beta-mediated side effects.
Paper Details　
Original Abstract of the Article :
Albuterol, in all marketed forms, is sold as a racemate, composed of a 50:50 mixture of (R)- and (S)-isomers. Racemic albuterol and the single isomer version (R)-albuterol (levalbuterol) were compared in a randomized, double-blind, dose-ranging five-way crossover study in patients (n = 20) with mild...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/02770900009055455

データ提供：米国国立医学図書館（NLM）

Levalbuterol vs. Racemic Albuterol for Asthma Treatment

Asthma, a chronic respiratory condition, can feel like a suffocating desert, with limited options for relief. This research delves into the world of bronchodilators, investigating the effectiveness of levalbuterol, a single-isomer version of albuterol, compared to racemic albuterol, a mixture of both isomers. The researchers embarked on a journey to compare the efficacy and safety of these two medications, seeking to find a more effective and well-tolerated path through the desert of asthma treatment.

The study, like a careful exploration of a desert oasis, investigated the bronchodilatory activity of different doses of levalbuterol and racemic albuterol, measuring their effects on lung function and monitoring for side effects. They found that levalbuterol offered comparable bronchodilatory effects to racemic albuterol, but with less marked effects on heart rate and potassium levels.

Finding a More Comfortable Path

The study suggests that levalbuterol could be a valuable alternative to racemic albuterol, potentially offering a more comfortable and well-tolerated treatment option. This finding offers a new pathway through the desert of asthma treatment, potentially leading to improved outcomes for individuals struggling with this condition.

Asthma Management and Patient Comfort

Choosing the right asthma medication is a crucial step in managing this condition. This study provides valuable information for clinicians and patients, highlighting the potential benefits of levalbuterol in terms of efficacy and side effect profile. It emphasizes the importance of considering individual patient needs and tailoring treatment strategies accordingly.

Dr.Camel's Conclusion

This study sheds light on the complex world of asthma treatment. It provides valuable insights into the efficacy and safety of levalbuterol compared to racemic albuterol, suggesting that levalbuterol could offer a more comfortable and well-tolerated treatment option for individuals with asthma. It reminds us that the journey towards better asthma management is an ongoing one, with new discoveries and improved treatments emerging on the horizon.

Date :
  1. Date Completed 2000-07-17
  2. Date Revised 2019-09-21
Further Info :

Pubmed ID

10883742

DOI: Digital Object Identifier

10.3109/02770900009055455

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.